Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies

Neurotoxicity is an important and common complication of chimeric antigen receptor-T cell therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of patients treated with CD19-directed chimeric antigen receptor-T cells for B-cell malignancies. Clinical manifestations incl...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	CNS drugs Ročník 32; číslo 12; s. 1091 - 1101
Hlavní autori:	Gust, Juliane, Taraseviciute, Agne, Turtle, Cameron J.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Cham Springer International Publishing 01.12.2018 Springer Nature B.V
Predmet:	Animal models Antigens Antigens, CD19 - metabolism Arthritis Blood-brain barrier Brain cancer CD19 antigen Cell activation Cell therapy Cerebrospinal fluid Chimeric antigen receptors Clinical trials Corticosteroids Cytokines Cytokines - blood Cytokines - cerebrospinal fluid Edema FDA approval Headache Humans Immunologic Factors - therapeutic use Immunotherapy Immunotherapy, Adoptive - methods Interleukin 6 Leading Article Leukemia Lymphocytes Lymphocytes B Lymphocytes T Lymphoma Medicine Medicine & Public Health Multiple myeloma Neurology Neurosciences Neurotoxicity Neurotoxicity Syndromes - epidemiology Neurotoxicity Syndromes - immunology Neurotoxicity Syndromes - metabolism Neurotoxicity Syndromes - therapy Pediatrics Pharmacotherapy Psychiatry Psychopharmacology Receptors, Antigen, T-Cell - metabolism Seizures Traumatic brain injury Young adults United States > US
ISSN:	1172-7047, 1179-1934, 1179-1934
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Neurotoxicity is an important and common complication of chimeric antigen receptor-T cell therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of patients treated with CD19-directed chimeric antigen receptor-T cells for B-cell malignancies. Clinical manifestations include headache, confusion, delirium, language disturbance, seizures and rarely, acute cerebral edema. Neurotoxicity is associated with cytokine release syndrome, which occurs in the setting of in-vivo chimeric antigen receptor-T cell activation and proliferation. The mechanisms that lead to neurotoxicity remain unknown, but data from patients and animal models suggest there is compromise of the blood–brain barrier, associated with high levels of cytokines in the blood and cerebrospinal fluid, as well as endothelial activation. Corticosteroids, interleukin-6-targeted therapies, and supportive care are frequently used to manage patients with neurotoxicity, but high-quality evidence of their efficacy is lacking.
AbstractList	Neurotoxicity is an important and common complication of chimeric antigen receptor-T cell therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of patients treated with CD19-directed chimeric antigen receptor-T cells for B-cell malignancies. Clinical manifestations include headache, confusion, delirium, language disturbance, seizures and rarely, acute cerebral edema. Neurotoxicity is associated with cytokine release syndrome, which occurs in the setting of in-vivo chimeric antigen receptor-T cell activation and proliferation. The mechanisms that lead to neurotoxicity remain unknown, but data from patients and animal models suggest there is compromise of the blood-brain barrier, associated with high levels of cytokines in the blood and cerebrospinal fluid, as well as endothelial activation. Corticosteroids, interleukin-6-targeted therapies, and supportive care are frequently used to manage patients with neurotoxicity, but high-quality evidence of their efficacy is lacking.Neurotoxicity is an important and common complication of chimeric antigen receptor-T cell therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of patients treated with CD19-directed chimeric antigen receptor-T cells for B-cell malignancies. Clinical manifestations include headache, confusion, delirium, language disturbance, seizures and rarely, acute cerebral edema. Neurotoxicity is associated with cytokine release syndrome, which occurs in the setting of in-vivo chimeric antigen receptor-T cell activation and proliferation. The mechanisms that lead to neurotoxicity remain unknown, but data from patients and animal models suggest there is compromise of the blood-brain barrier, associated with high levels of cytokines in the blood and cerebrospinal fluid, as well as endothelial activation. Corticosteroids, interleukin-6-targeted therapies, and supportive care are frequently used to manage patients with neurotoxicity, but high-quality evidence of their efficacy is lacking. Neurotoxicity is an important and common complication of chimeric antigen receptor-T cell therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of patients treated with CD19-directed chimeric antigen receptor-T cells for B-cell malignancies. Clinical manifestations include headache, confusion, delirium, language disturbance, seizures and rarely, acute cerebral edema. Neurotoxicity is associated with cytokine release syndrome, which occurs in the setting of in-vivo chimeric antigen receptor-T cell activation and proliferation. The mechanisms that lead to neurotoxicity remain unknown, but data from patients and animal models suggest there is compromise of the blood–brain barrier, associated with high levels of cytokines in the blood and cerebrospinal fluid, as well as endothelial activation. Corticosteroids, interleukin-6-targeted therapies, and supportive care are frequently used to manage patients with neurotoxicity, but high-quality evidence of their efficacy is lacking.
Author	Taraseviciute, Agne Gust, Juliane Turtle, Cameron J.
AuthorAffiliation	5 Department of Medicine, University of Washington, Seattle, WA, USA 3 Department of Pediatrics, University of Southern California, Los Angeles, CA, USA 2 Division of Pediatric Neurology, Department of Neurology, University of Washington, Seattle, WA, USA 1 Center for Integrative Brain Research, Seattle Children’s Research Institute, Seattle, WA, USA 4 Clinical Research Division and Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
AuthorAffiliation_xml	– name: 3 Department of Pediatrics, University of Southern California, Los Angeles, CA, USA – name: 2 Division of Pediatric Neurology, Department of Neurology, University of Washington, Seattle, WA, USA – name: 1 Center for Integrative Brain Research, Seattle Children’s Research Institute, Seattle, WA, USA – name: 4 Clinical Research Division and Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA – name: 5 Department of Medicine, University of Washington, Seattle, WA, USA
Author_xml	– sequence: 1 givenname: Juliane surname: Gust fullname: Gust, Juliane organization: Center for Integrative Brain Research, Seattle Children’s Research Institute, Division of Pediatric Neurology, Department of Neurology, University of Washington – sequence: 2 givenname: Agne surname: Taraseviciute fullname: Taraseviciute, Agne organization: Department of Pediatrics, University of Southern California – sequence: 3 givenname: Cameron J. surname: Turtle fullname: Turtle, Cameron J. email: cturtle@fhcrc.org organization: Clinical Research Division and Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/30387077$$D View this record in MEDLINE/PubMed
BookMark	eNp9kUtP3DAUha0KxPsHdFNF6oaNqV-J403FKOVRCbUSGtaW49zMGGXiwU6g_HucDqWA1G5sy_7Ouff67KOt3veA0EdKTigh8ksUhBUcE1pikpcMqw9oj1KpMFVcbP0-MyyJkLtoP8ZbQojgRbGDdjnhpSRS7qHTHzAGP_hfzrrhMZvF6K0zAzTZgxuWWfWNKjw3YQHTVTW7xvOsgq7L5ksIZu0gHqLt1nQRjp73A3RzfjavLvHVz4vv1ewKWyHJgAtFTFMqVZfCsta2AkQt80ZRLkWZm5yVhlllCsEtF0wCA8p5bUTDSVrrlh-grxvf9VivoLHQD8F0eh3cyoRH7Y3Tb196t9QLf68lUzmleTI4fjYI_m6EOOiVizbNYnrwY9SMJpBzXtCEfn6H3vox9Gm8RCme50qyifr0uqOXVv58bgLoBrDBxxigfUEo0VOAehOgTgHqKUCtkka-06RczOD8NJTr_qtkG2VMVfoFhL9N_1v0BDDsrSk
CitedBy_id	crossref_primary_10_1186_s13046_021_02148_6 crossref_primary_10_1136_jitc_2022_005898 crossref_primary_10_3390_molecules27123798 crossref_primary_10_1007_s13402_021_00593_1 crossref_primary_10_1016_S2352_3026_21_00238_6 crossref_primary_10_1186_s12967_024_06052_3 crossref_primary_10_1038_s43018_025_00968_5 crossref_primary_10_1007_s00134_024_07576_4 crossref_primary_10_1097_WNP_0000000000000669 crossref_primary_10_3390_cancers14071677 crossref_primary_10_1016_j_jtct_2023_01_004 crossref_primary_10_1136_jitc_2024_009174 crossref_primary_10_3390_cancers13081955 crossref_primary_10_1016_j_jcyt_2020_01_015 crossref_primary_10_1097_JAT_0000000000000183 crossref_primary_10_1016_j_prp_2021_153723 crossref_primary_10_1007_s10555_024_10227_1 crossref_primary_10_3389_fmed_2025_1553966 crossref_primary_10_1007_s00415_021_10766_5 crossref_primary_10_1038_s41409_020_01006_x crossref_primary_10_1002_ana_25502 crossref_primary_10_1002_pbc_29734 crossref_primary_10_1111_imr_13273 crossref_primary_10_1007_s11136_022_03258_0 crossref_primary_10_1136_jitc_2021_003486 crossref_primary_10_1016_j_bbmt_2019_09_037 crossref_primary_10_3389_fimmu_2023_1068625 crossref_primary_10_3389_fphar_2021_720692 crossref_primary_10_1007_s11940_019_0580_3 crossref_primary_10_1016_j_jchromb_2021_122944 crossref_primary_10_1097_CJI_0000000000000391 crossref_primary_10_3389_fimmu_2022_1079181 crossref_primary_10_3390_cancers14030843 crossref_primary_10_1016_j_blre_2021_100883 crossref_primary_10_1016_j_annonc_2020_10_478 crossref_primary_10_1055_s_0042_1742442 crossref_primary_10_1111_cns_13569 crossref_primary_10_1093_neuonc_noab174 crossref_primary_10_1182_bloodadvances_2022008119 crossref_primary_10_3390_ijms22136716 crossref_primary_10_3390_ijms23105515 crossref_primary_10_1016_j_drudis_2021_10_012 crossref_primary_10_3389_fimmu_2022_927153 crossref_primary_10_4110_in_2025_25_e23 crossref_primary_10_1007_s00134_020_06193_1 crossref_primary_10_1080_20565623_2024_2422786 crossref_primary_10_1097_CJI_0000000000000437 crossref_primary_10_1002_pbc_28635 crossref_primary_10_1007_s00415_023_11595_4 crossref_primary_10_1016_j_clml_2019_09_598 crossref_primary_10_3390_jcm8060884 crossref_primary_10_1016_j_yrtph_2021_105064 crossref_primary_10_3389_fimmu_2021_627650 crossref_primary_10_1016_j_pediatrneurol_2020_06_014 crossref_primary_10_1017_cjn_2024_7 crossref_primary_10_1007_s10555_020_09847_0 crossref_primary_10_1016_j_radcr_2022_12_053 crossref_primary_10_1038_s41582_025_01112_8 crossref_primary_10_1212_WNL_0000000000213535 crossref_primary_10_1136_archdischild_2024_328263 crossref_primary_10_1007_s12272_019_01143_y crossref_primary_10_1038_s41598_023_46114_y crossref_primary_10_1155_2020_4241864 crossref_primary_10_3390_cancers17172876 crossref_primary_10_1007_s00063_024_01230_z crossref_primary_10_3389_fimmu_2022_871661 crossref_primary_10_1002_jha2_274 crossref_primary_10_1186_s12885_023_11753_x crossref_primary_10_1002_smtd_202401783 crossref_primary_10_1080_14712598_2020_1729735 crossref_primary_10_3389_fimmu_2024_1380451 crossref_primary_10_1186_s12935_024_03315_3 crossref_primary_10_1186_s40959_022_00132_3 crossref_primary_10_1016_j_medine_2022_02_005 crossref_primary_10_1186_s12987_022_00342_y crossref_primary_10_1007_s44272_025_00044_0 crossref_primary_10_1016_j_jns_2021_117405 crossref_primary_10_3390_ijms251810177 crossref_primary_10_1055_s_0041_1733788 crossref_primary_10_3389_fimmu_2022_1050994 crossref_primary_10_1182_bloodadvances_2020001450 crossref_primary_10_1038_s41568_020_00323_z crossref_primary_10_1186_s40425_019_0673_2 crossref_primary_10_1111_bjh_17527 crossref_primary_10_1158_2326_6066_CIR_22_0962 crossref_primary_10_1016_j_taap_2023_116628 crossref_primary_10_1007_s11904_020_00519_w crossref_primary_10_3390_cancers15133346 crossref_primary_10_1038_s41392_019_0070_9 crossref_primary_10_3389_fonc_2022_836452 crossref_primary_10_1007_s43152_023_00046_x crossref_primary_10_1038_s41571_020_00456_y crossref_primary_10_3389_fimmu_2022_887471 crossref_primary_10_3390_cancers13030438 crossref_primary_10_1016_j_genhosppsych_2020_05_008 crossref_primary_10_1097_CCO_0000000000000653 crossref_primary_10_1007_s10238_020_00628_1 crossref_primary_10_1097_HS9_0000000000000802 crossref_primary_10_3390_ijms25010644 crossref_primary_10_1038_s41409_021_01526_0 crossref_primary_10_1016_j_ejphar_2024_176618 crossref_primary_10_1212_CPJ_0000000000200488 crossref_primary_10_1177_08850666231205264 crossref_primary_10_1007_s00393_025_01703_2 crossref_primary_10_1016_j_jneuroim_2025_578717 crossref_primary_10_1007_s11684_021_0843_8 crossref_primary_10_1038_s41392_023_01521_5 crossref_primary_10_1186_s13613_022_01036_2 crossref_primary_10_3390_ijms21228655 crossref_primary_10_3390_jcm11030623 crossref_primary_10_1016_j_psym_2020_06_015 crossref_primary_10_1186_s13020_020_00309_x crossref_primary_10_1097_MEJ_0000000000001086 crossref_primary_10_1016_j_jtct_2023_10_006 crossref_primary_10_1136_bmj_2021_068956 crossref_primary_10_3390_cancers15041249 crossref_primary_10_1007_s00415_020_10237_3 crossref_primary_10_1182_blood_2021013733 crossref_primary_10_3390_vaccines8040708 crossref_primary_10_1038_s41568_024_00700_y crossref_primary_10_1212_WNL_0000000000213501 crossref_primary_10_1182_blood_2020006619 crossref_primary_10_5306_wjco_v12_i5_290 crossref_primary_10_7759_cureus_14494 crossref_primary_10_1016_j_jaclp_2021_08_009 crossref_primary_10_2217_imt_2020_0161 crossref_primary_10_3390_cancers12113445 crossref_primary_10_1016_S1470_2045_19_30461_9 crossref_primary_10_1007_s00508_024_02451_0 crossref_primary_10_1016_j_ccell_2021_01_007 crossref_primary_10_14336_AD_2024_0579 crossref_primary_10_1038_s41417_025_00931_7 crossref_primary_10_3389_fneur_2023_1110647 crossref_primary_10_1111_1759_7714_14375 crossref_primary_10_1002_ajh_27198 crossref_primary_10_3389_fonc_2023_1206983 crossref_primary_10_1016_j_intimp_2023_111095 crossref_primary_10_1182_blood_2019003690 crossref_primary_10_1016_j_jaut_2022_102873 crossref_primary_10_1016_j_clml_2024_12_011 crossref_primary_10_1007_s11940_020_00638_0 crossref_primary_10_1212_WNL_0000000000012182 crossref_primary_10_1016_j_cell_2021_02_011 crossref_primary_10_3389_fimmu_2020_577027 crossref_primary_10_1007_s00262_024_03661_1 crossref_primary_10_1016_j_medin_2020_06_014 crossref_primary_10_1186_s13045_019_0801_y crossref_primary_10_33448_rsd_v14i9_49533 crossref_primary_10_3389_fimmu_2021_765097 crossref_primary_10_1007_s00277_024_05640_z crossref_primary_10_3389_fimmu_2020_569117 crossref_primary_10_3390_pharmaceutics16091228 crossref_primary_10_1007_s10072_024_07481_0 crossref_primary_10_3389_fimmu_2021_681984 crossref_primary_10_3389_fonc_2022_787108 crossref_primary_10_1016_j_canlet_2022_215762 crossref_primary_10_1097_MS9_0000000000001375 crossref_primary_10_1111_jhn_13210 crossref_primary_10_1002_ajh_25445 crossref_primary_10_3390_biomedicines10092286 crossref_primary_10_1007_s15015_020_2557_1 crossref_primary_10_1007_s13312_024_3300_3 crossref_primary_10_1212_CPJ_0000000000001130 crossref_primary_10_1634_theoncologist_2019_0395 crossref_primary_10_3390_jcm12041446 crossref_primary_10_46989_001c_117961 crossref_primary_10_3390_cancers15174253 crossref_primary_10_3389_fmed_2023_1199146 crossref_primary_10_3390_ijms252011028 crossref_primary_10_1016_j_jaut_2024_103350 crossref_primary_10_1186_s12967_025_06608_x crossref_primary_10_1186_s40779_023_00486_4 crossref_primary_10_1016_j_bbmt_2019_08_015 crossref_primary_10_1097_CJI_0000000000000416 crossref_primary_10_1007_s10555_019_09827_z
Cites_doi	10.1126/scitranslmed.aaa0984 10.1158/2159-8290.CD-17-0698 10.1158/2159-8290.CD-16-0040 10.1038/75068 10.1056/NEJMoa1708566 10.4161/mabs.1.5.9497 10.1038/nrclinonc.2017.128 10.1146/annurev-med-062315-120245 10.1182/blood-2011-04-348540 10.1016/j.jim.2016.03.005 10.1016/j.retram.2018.03.004 10.1182/blood.V130.Suppl_1.1547.1547 10.1038/mt.2013.154 10.1089/neu.2016.4472 10.1126/scitranslmed.aaf8621 10.1038/nrclinonc.2018.19 10.1126/scitranslmed.3005930 10.1172/JCI94306 10.1182/blood-2016-04-711903 10.1097/00001813-199502000-00002 10.1200/JCO.2014.56.2025 10.14694/EDBK_180328 10.1056/NEJMoa1613849 10.1200/JCO.2017.35.15_suppl.7024 10.1038/mt.2013.17 10.1017/S147895151600095X 10.1200/JCO.2014.58.0225 10.1097/WNP.0000000000000166 10.1182/blood-2016-04-703751 10.4103/1817-1745.147572 10.1002/pros.23214 10.1158/1078-0432.CCR-15-0428 10.1186/s13045-018-0571-y 10.1038/s41591-018-0041-7 10.1182/blood-2017-02-769208 10.1158/2159-8290.CD-17-1368 10.1038/nrd.2016.278 10.1182/blood.V126.23.3769.3769 10.1634/theoncologist.2018-0028 10.1196/annals.1321.010 10.1056/NEJMoa1610497 10.1158/1078-0432.CCR-12-3349 10.1186/1741-7015-11-185 10.1007/s11427-016-5023-8 10.1089/hum.2018.001 10.1172/JCI85309 10.1182/blood-2014-12-580068 10.1016/S0140-6736(14)61403-3 10.1111/jnc.13408 10.1016/S0006-8993(99)02189-7 10.1182/blood-2017-08-802413 10.4161/viru.24530 10.1016/j.retram.2018.03.003 10.1182/blood.V128.22.586.586 10.1056/NEJMoa1407222 10.1038/nrclinonc.2017.148 10.1186/s40425-017-0289-3 10.1016/j.ymthe.2017.03.010 10.1126/scitranslmed.3008226 10.1016/j.molmed.2017.03.002 10.3390/ijms16059949 10.1200/JCO.2017.35.15_suppl.3019 10.1016/j.coi.2018.03.002 10.1038/nm.4441 10.1158/2159-8290.CD-17-1319 10.1182/blood-2008-05-155846 10.1056/NEJMoa1707447 10.1073/pnas.0808698106 10.1038/s41591-018-0036-4 10.1182/blood.V128.22.2803.2803 10.1002/cpt.950 10.1007/s40744-018-0102-x 10.1056/NEJMoa1709919 10.1158/1078-0432.CCR-16-1365 10.1517/14712598.5.5.683 10.1007/s00262-017-2034-7 10.4049/jimmunol.142.1.144 10.1016/j.semarthrit.2014.07.006 10.1093/rheumatology/kev382 10.1200/JCO.2017.72.8519 10.2147/AHMT.S109495 10.1182/blood-2017-06-793141 10.1056/NEJMoa1709866 10.1038/s41591-018-0010-1 10.1016/j.ymthe.2018.04.006
ContentType	Journal Article
Copyright	Springer Nature Switzerland AG 2018 Copyright Springer Nature B.V. Dec 2018
Copyright_xml	– notice: Springer Nature Switzerland AG 2018 – notice: Copyright Springer Nature B.V. Dec 2018
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 4T- 7QP 7TK 7X7 7XB 88E 88G 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ K9. M0S M1P M2M PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM
DOI	10.1007/s40263-018-0582-9
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Docstoc Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Psychology Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition Docstoc ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE ProQuest One Psychology
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Pharmacy, Therapeutics, & Pharmacology
EISSN	1179-1934
EndPage	1101
ExternalDocumentID	PMC7295115 30387077 10_1007_s40263_018_0582_9
Genre	Journal Article Review
GeographicLocations	United States--US
GeographicLocations_xml	– name: United States--US
GrantInformation_xml	– fundername: NINDS NIH HHS grantid: K12 NS098482
GroupedDBID	--- -EM 0R~ 29B 2JY 36B 3V. 4.4 406 53G 5GY 6I2 6PF 7X7 88E 8FI 8FJ 8R4 8R5 95. AAAUJ AACDK AADNT AAIAL AAIKX AAJKR AAKAS AASML AATNV AAWTL AAYQN AAYTO ABAKF ABDZT ABFTV ABIPD ABIVO ABJNI ABJOX ABKCH ABKMS ABKTR ABPLI ABTKH ABTMW ABUWG ABWHX ABXPI ACAOD ACCOQ ACCUX ACDTI ACGFS ACMLO ACPIV ACPRK ACZOJ ADBBV ADFZG ADHHG ADJJI ADQRH ADRFC ADURQ ADZCM ADZKW AEBTG AEFQL AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AEYRQ AFBBN AFKRA AFZKB AGAYW AGDGC AGQEE AGQMX AGRTI AHIZS AHMBA AHSBF AIAKS AIGIU AILAN ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW AMYLF ASPBG AUKKA AVWKF AWSVR AXYYD AZFZN AZQEC A~4 BENPR BGNMA BPHCQ BVXVI BYPQX CAG CCPQU COF CS3 DCUDU DPUIP DU5 DWQXO EBLON EBS EJD EMOBN ESX F5P FEDTE FIGPU FLLZZ FNLPD FSGXE FYUFA GNUQQ H13 HG6 HMCUK HVGLF IAO IEA IHR IMOTQ INH INR IPY ITC IWAJR J-C JZLTJ LLZTM M1P M2M M4Y NQJWS NU0 O9- OAC OPC OVD P2P PQQKQ PROAC PSQYO PSYQQ Q2X ROL RSV RZALA SISQX SJYHP SNPRN SOHCF SOJ SPKJE SRMVM SSLCW TEORI TSG U9L UG4 UKHRP UTJUX VDBLX VFIZW W48 YFH YQY ~JE AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFFHD AFHIU AFOHR AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM 4T- 7QP 7TK 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c470t-690ad899b84c2fcf4e4b75d9137485a528a2c9a643c3427e2e133ba4d30ba4bf3
IEDL.DBID	RSV
ISICitedReferencesCount	199
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000452919800002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1172-7047 1179-1934
IngestDate	Tue Nov 04 01:44:28 EST 2025 Wed Oct 01 15:10:29 EDT 2025 Sat Nov 08 00:17:19 EST 2025 Thu Apr 03 06:58:51 EDT 2025 Sat Nov 29 06:09:11 EST 2025 Tue Nov 18 21:09:28 EST 2025 Fri Feb 21 02:28:46 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	12
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c470t-690ad899b84c2fcf4e4b75d9137485a528a2c9a643c3427e2e133ba4d30ba4bf3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
OpenAccessLink	https://www.ncbi.nlm.nih.gov/pmc/articles/7295115
PMID	30387077
PQID	2193559721
PQPubID	33311
PageCount	11
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_7295115 proquest_miscellaneous_2129533361 proquest_journals_2193559721 pubmed_primary_30387077 crossref_primary_10_1007_s40263_018_0582_9 crossref_citationtrail_10_1007_s40263_018_0582_9 springer_journals_10_1007_s40263_018_0582_9
PublicationCentury	2000
PublicationDate	20181200 2018-12-00 20181201
PublicationDateYYYYMMDD	2018-12-01
PublicationDate_xml	– month: 12 year: 2018 text: 20181200
PublicationDecade	2010
PublicationPlace	Cham
PublicationPlace_xml	– name: Cham – name: New Zealand – name: Auckland
PublicationTitle	CNS drugs
PublicationTitleAbbrev	CNS Drugs
PublicationTitleAlternate	CNS Drugs
PublicationYear	2018
Publisher	Springer International Publishing Springer Nature B.V
Publisher_xml	– name: Springer International Publishing – name: Springer Nature B.V
References	Annesley, Summers, Ceppi, Gardner (CR8) 2018; 103 Junghans, Ma, Rathore, Gomes, Bais, Lo (CR36) 2016; 76 Argaw, Gurfein, Zhang, Zameer, John (CR62) 2009; 106 Turtle, Hay, Hanafi, Li, Cherian, Chen (CR14) 2017; 35 Chen, Li, Chintala, Tano, Adusumilli (CR19) 2018; 51 Newick, O’Brien, Moon, Albelda (CR33) 2017; 68 Curtis, Perez-Gutthann, Suissa, Napalkov, Singh, Thompson (CR73) 2015; 44 Page, Liles (CR61) 2013; 4 Maude, Teachey, Porter, Grupp (CR76) 2015; 125 Ritchie, Neeson, Khot, Peinert, Tai, Tainton (CR31) 2013; 21 CR78 Brentjens, Davila, Riviere, Park, Wang, Cowell (CR15) 2013; 5 Obstfeld, Frey, Mansfield, Lacey, June, Porter (CR55) 2017; 130 Wingerchuk, Weinshenker (CR85) 2013; 19 Stone, Tuckwell, Dimonaco, Klearman, Aringer, Blockmans (CR75) 2017; 377 DeAngelo (CR24) 2017; 5 Le, Li, Yuan, Shord, Nie, Habtemariam (CR77) 2018; 23 Lamers, Sleijfer, van Steenbergen, van Elzakker, van Krimpen, Groot (CR37) 2013; 21 Koehler (CR82) 1995; 6 Maude, Laetsch, Buechner, Rives, Boyer, Bittencourt (CR6) 2018; 378 Neelapu, Tummala, Kebriaei, Wierda, Gutierrez, Locke (CR50) 2018; 15 Lee, Kochenderfer, Stetler-Stevenson, Cui, Delbrook, Feldman (CR5) 2015; 385 Taraseviciute, Tkachev, Ponce, Turtle, Snyder, Liggitt (CR48) 2018; 8 Kukreti, Mohseni-Bod, Drake (CR92) 2014; 9 Maude, Frey, Shaw, Aplenc, Barrett, Bunin (CR7) 2014; 371 Feng, Guo, Dai, Wang, Li, Jia (CR35) 2016; 59 Chen, Teachey, Pequignot, Frey, Porter, Maude (CR79) 2016; 434 Shah, Huynh, Sender, Lee, Castro, Wierda (CR88) 2016; 128 Brentjens, Rivière, Park, Davila, Wang, Stefanski (CR25) 2011; 118 Rosário, Zandman-Goddard, Meyron-Holtz, D’Cruz, Shoenfeld (CR59) 2013; 11 Gardner, Leger, Annesley, Summers, Rivers, Gust (CR81) 2016; 128 Grevich, Shenoi (CR89) 2017; 8 Ramos, Ballard, Zhang, Dakhova, Gee, Mei (CR27) 2017; 127 Gust, Hay, Hanafi, Li, Myerson, Gonzalez-Cuyar (CR23) 2017; 7 Venkiteshwaran (CR71) 2009; 1 Mihara, Nishimoto, Ohsugi (CR70) 2005; 5 Hay, Hanafi, Li, Gust, Liles, Wurfel (CR20) 2017; 130 Chang, Chen (CR1) 2017; 23 CR44 Schuster, Svoboda, Chong, Nasta, Mato, Anak (CR11) 2017; 377 Gardner, Finney, Annesley, Brakke, Summers, Leger (CR4) 2017; 22 Fraietta, Lacey, Orlando, Pruteanu-Malinici, Gohil, Lundh (CR16) 2018; 24 Turtle, Hanafi, Berger, Gooley, Cherian, Hudecek (CR3) 2016; 126 Rochfort, Collins, McLoughlin, Cummins (CR63) 2016; 136 Santomasso, Park, Salloum, Rivière, Flynn, Mead (CR49) 2018; 8 Saharinen, Eklund, Alitalo (CR90) 2017; 16 Brown, Alizadeh, Starr, Weng, Wagner, Naranjo (CR42) 2016; 375 Nishimoto, Terao, Mima, Nakahara, Takagi, Kakehi (CR80) 2008; 112 Ahmed, Brawley, Hegde, Robertson, Ghazi, Gerken (CR34) 2015; 33 Atreya, Mudter, Finotto, Müllberg, Jostock, Wirtz (CR69) 2000; 6 Rheingold, Chen, Maude, Aplenc, Barker, Barrett (CR47) 2015; 126 Kurzrock, Voorhees, Casper, Furman, Fayad, Lonial (CR87) 2013; 19 Jirik, Podor, Hirano, Kishimoto, Loskutoff, Carson (CR56) 1989; 142 CR17 Park, Rivière, Gonen, Wang, Sénéchal, Curran (CR2) 2018; 378 Brown, Badie, Barish, Weng, Ostberg, Chang (CR41) 2015; 21 Fry, Shah, Orentas, Stetler-Stevenson, Yuan, Ramakrishna (CR28) 2018; 24 Neelapu, Locke, Bartlett, Lekakis, Miklos, Jacobson (CR12) 2017; 377 Gauthier, Turtle (CR68) 2018; 66 Friedman, Garrett, Evans, Horton, Latimer, Seidel (CR18) 2018; 29 Park, Santomasso, Riviere, Senechal, Wang, Purdon (CR60) 2017; 35 Porter, Frey, Wood, Weng, Grupp (CR26) 2018; 11 Brudno, Kochenderfer (CR67) 2016; 127 Kochenderfer, Dudley, Kassim, Somerville, Carpenter, Stetler-Stevenson (CR10) 2015; 33 Prudent, Breitbart (CR43) 2017; 15 Chesnut, Temkin, Dikmen, Rondina, Videtta, Petroni (CR91) 2018; 35 Thistlethwaite, Gilham, Guest, Rothwell, Pillai, Burt (CR38) 2017; 66 Berkovich (CR84) 2016; 22 O’Rourke, Nasrallah, Desai, Melenhorst, Mansfield, Morrissette (CR40) 2017; 9 Lee, Gardner, Porter, Louis, Ahmed, Jensen (CR22) 2014; 124 Davila, Riviere, Wang, Bartido, Park, Curran (CR65) 2014; 6 Grupp (CR52) 2018; 66 Elenkov (CR86) 2004; 1024 Brudno, Kochenderfer (CR13) 2018; 15 Herman, Abend, Bleck, Chapman, Drislane, Emerson (CR51) 2015; 32 Rubbert-Roth, Furst, Nebesky, Jin, Berber (CR72) 2018; 5 Norelli, Camisa, Barbiera, Falcone, Purevdorj, Genua (CR53) 2018; 24 Santomasso, Park, Riviere, Mead, Halton, Diamonte (CR46) 2017; 35 Tarp, Amarilyo, Foeldvari, Christensen, Woo, Cohen (CR74) 2016; 55 Zhang, Wang, Yang, Wang, Li, Li (CR39) 2017; 25 Pennell, Barnum, McDonald-Hyman, Panoskaltsis-Mortari, Riddle, Xiong (CR54) 2018; 26 Giavridis, van der Stegen, Eyquem, Hamieh, Piersigilli, Sadelain (CR58) 2018; 24 Ali, Shi, Maric, Wang, Stroncek, Rose (CR30) 2016; 128 Michinaga, Koyama (CR83) 2015; 16 CR64 Reyes, Fabry, Coe (CR57) 1999; 851 Turtle, Hanafi, Berger, Hudecek, Pender, Robinson (CR9) 2016; 8 Teachey, Lacey, Shaw, Melenhorst, Maude, Frey (CR21) 2016; 6 Teachey, Bishop, Maloney, Grupp (CR66) 2018; 15 Wang, Wu, Wang, Guo, Dai, Wang (CR29) 2017; 23 Yeku, Li, Brentjens (CR32) 2017; 37 Locke, Neelapu, Bartlett, Lekakis, Jacobson, Braunschweig (CR45) 2017; 130 CE Brown (582_CR42) 2016; 375 582_CR17 V Kukreti (582_CR92) 2014; 9 SR Rheingold (582_CR47) 2015; 126 S Tarp (582_CR74) 2016; 55 RA Gardner (582_CR4) 2017; 22 A Venkiteshwaran (582_CR71) 2009; 1 C Rosário (582_CR59) 2013; 11 IJ Elenkov (582_CR86) 2004; 1024 DJ DeAngelo (582_CR24) 2017; 5 582_CR64 RJ Brentjens (582_CR15) 2013; 5 RR Berkovich (582_CR84) 2016; 22 P Saharinen (582_CR90) 2017; 16 RP Junghans (582_CR36) 2016; 76 JH Park (582_CR60) 2017; 35 CH Lamers (582_CR37) 2013; 21 JR Curtis (582_CR73) 2015; 44 RM Chesnut (582_CR91) 2018; 35 SS Neelapu (582_CR12) 2017; 377 JN Brudno (582_CR13) 2018; 15 N Chen (582_CR19) 2018; 51 DT Teachey (582_CR66) 2018; 15 AE Obstfeld (582_CR55) 2017; 130 DS Ritchie (582_CR31) 2013; 21 FR Jirik (582_CR56) 1989; 142 TJ Fry (582_CR28) 2018; 24 BD Santomasso (582_CR49) 2018; 8 SL Maude (582_CR7) 2014; 371 TM Reyes (582_CR57) 1999; 851 R Kurzrock (582_CR87) 2013; 19 KA Hay (582_CR20) 2017; 130 DT Teachey (582_CR21) 2016; 6 A Rubbert-Roth (582_CR72) 2018; 5 B Shah (582_CR88) 2016; 128 FC Thistlethwaite (582_CR38) 2017; 66 M Mihara (582_CR70) 2005; 5 RJ Brentjens (582_CR25) 2011; 118 SJ Schuster (582_CR11) 2017; 377 DM Wingerchuk (582_CR85) 2013; 19 CE Brown (582_CR41) 2015; 21 ZL Chang (582_CR1) 2017; 23 CJ Turtle (582_CR3) 2016; 126 K Newick (582_CR33) 2017; 68 PJ Koehler (582_CR82) 1995; 6 C-M Wang (582_CR29) 2017; 23 582_CR78 A Taraseviciute (582_CR48) 2018; 8 T Giavridis (582_CR58) 2018; 24 R Gardner (582_CR81) 2016; 128 JH Stone (582_CR75) 2017; 377 CA Ramos (582_CR27) 2017; 127 DW Lee (582_CR5) 2015; 385 DW Lee (582_CR22) 2014; 124 N Nishimoto (582_CR80) 2008; 112 KM Friedman (582_CR18) 2018; 29 JN Brudno (582_CR67) 2016; 127 R Atreya (582_CR69) 2000; 6 SA Ali (582_CR30) 2016; 128 DM O’Rourke (582_CR40) 2017; 9 CJ Turtle (582_CR14) 2017; 35 582_CR44 JN Kochenderfer (582_CR10) 2015; 33 CJ Turtle (582_CR9) 2016; 8 CA Pennell (582_CR54) 2018; 26 S Grevich (582_CR89) 2017; 8 FL Locke (582_CR45) 2017; 130 SS Neelapu (582_CR50) 2018; 15 S Grupp (582_CR52) 2018; 66 M Norelli (582_CR53) 2018; 24 N Ahmed (582_CR34) 2015; 33 V Prudent (582_CR43) 2017; 15 S Michinaga (582_CR83) 2015; 16 J Gust (582_CR23) 2017; 7 K Feng (582_CR35) 2016; 59 J Gauthier (582_CR68) 2018; 66 KD Rochfort (582_CR63) 2016; 136 C Zhang (582_CR39) 2017; 25 ST Herman (582_CR51) 2015; 32 SL Maude (582_CR6) 2018; 378 AT Argaw (582_CR62) 2009; 106 RQ Le (582_CR77) 2018; 23 JH Park (582_CR2) 2018; 378 D Porter (582_CR26) 2018; 11 ML Davila (582_CR65) 2014; 6 F Chen (582_CR79) 2016; 434 JA Fraietta (582_CR16) 2018; 24 SL Maude (582_CR76) 2015; 125 O Yeku (582_CR32) 2017; 37 B Santomasso (582_CR46) 2017; 35 AV Page (582_CR61) 2013; 4 CE Annesley (582_CR8) 2018; 103
References_xml	– volume: 385 start-page: 517 year: 2015 end-page: 528 ident: CR5 article-title: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial publication-title: Lancet – volume: 19 start-page: 944 year: 2013 end-page: 967 ident: CR85 article-title: Acute disseminated encephalomyelitis, transverse myelitis, and neuromyelitis optica publication-title: Contin Minneap Minn – volume: 15 start-page: 47 year: 2018 end-page: 62 ident: CR50 article-title: Chimeric antigen receptor T-cell therapy: assessment and management of toxicities publication-title: Nat Rev Clin Oncol – volume: 23 start-page: 943 issue: 8 year: 2018 end-page: 947 ident: CR77 article-title: FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome publication-title: Oncologist – volume: 5 start-page: 683 year: 2005 end-page: 690 ident: CR70 article-title: The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody publication-title: Expert Opin Biol Ther – volume: 35 start-page: 54 year: 2018 end-page: 63 ident: CR91 article-title: A method of managing severe traumatic brain injury in the absence of intracranial pressure monitoring: the imaging and clinical examination protocol publication-title: J Neurotrauma – volume: 25 start-page: 1248 year: 2017 end-page: 1258 ident: CR39 article-title: Phase I escalating-dose trial of CAR-T therapy targeting CEA metastatic colorectal cancers publication-title: Mol Ther J Am Soc Gene Ther – volume: 6 start-page: 664 year: 2016 end-page: 679 ident: CR21 article-title: Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia publication-title: Cancer Discov – volume: 15 start-page: 218 year: 2018 ident: CR66 article-title: Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit “ALL” publication-title: Nat Rev Clin Oncol – volume: 103 start-page: 591 year: 2018 end-page: 598 ident: CR8 article-title: The evolution and future of CAR T cells for B-cell acute lymphoblastic leukemia publication-title: Clin Pharmacol Ther – volume: 128 start-page: 1688 year: 2016 end-page: 1700 ident: CR30 article-title: T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma publication-title: Blood – volume: 66 start-page: 50 issue: 2 year: 2018 end-page: 52 ident: CR68 article-title: Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy publication-title: Curr Res Transl Med – volume: 125 start-page: 4017 year: 2015 end-page: 4023 ident: CR76 article-title: CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia publication-title: Blood – volume: 434 start-page: 1 year: 2016 end-page: 8 ident: CR79 article-title: Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy publication-title: J Immunol Methods – volume: 128 start-page: 2803 year: 2016 ident: CR88 article-title: High rates of minimal residual disease-negative (MRD−) complete responses (CR) in adult and pediatric and patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) treated with KTE-C19 (anti-CD19 chimeric antigen receptor [CAR] T cells): preliminary results of the ZUMA-3 and ZUMA-4 trials publication-title: Blood – volume: 59 start-page: 468 year: 2016 end-page: 479 ident: CR35 article-title: Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer publication-title: Sci China Life Sci – volume: 142 start-page: 144 year: 1989 end-page: 147 ident: CR56 article-title: Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells publication-title: J Immunol – volume: 24 start-page: 20 year: 2018 ident: CR28 article-title: CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy publication-title: Nat Med – volume: 22 start-page: 799 year: 2016 end-page: 814 ident: CR84 article-title: Acute multiple sclerosis relapse publication-title: Contin Minneap Minn – volume: 8 start-page: 355ra116 year: 2016 ident: CR9 article-title: Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 and CD4 CD19-specific chimeric antigen receptor-modified T cells publication-title: Sci Transl Med – volume: 11 start-page: 185 year: 2013 ident: CR59 article-title: The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome publication-title: BMC Med – volume: 15 start-page: 499 year: 2017 end-page: 503 ident: CR43 article-title: Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute lymphoblastic leukemia publication-title: Palliat Support Care – volume: 9 start-page: eaaa0984 issue: 399 year: 2017 ident: CR40 article-title: A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aaa0984 – volume: 21 start-page: 2122 year: 2013 end-page: 2129 ident: CR31 article-title: Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia publication-title: Mol Ther J Am Soc Gene Ther – volume: 68 start-page: 139 year: 2017 end-page: 152 ident: CR33 article-title: CAR T cell therapy for solid tumors publication-title: Annu Rev Med – volume: 5 start-page: 177ra38 year: 2013 ident: CR15 article-title: CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia publication-title: Sci Transl Med – volume: 8 start-page: 750 year: 2018 end-page: 763 ident: CR48 article-title: Chimeric antigen receptor T cell-mediated neurotoxicity in non-human primates publication-title: Cancer Discov – volume: 35 start-page: 7024 year: 2017 ident: CR60 article-title: Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL publication-title: J Clin Oncol – volume: 112 start-page: 3959 year: 2008 end-page: 3964 ident: CR80 article-title: Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease publication-title: Blood – volume: 6 start-page: 19 year: 1995 end-page: 33 ident: CR82 article-title: Use of corticosteroids in neuro-oncology publication-title: Anticancer Drugs – volume: 21 start-page: 4062 year: 2015 end-page: 4072 ident: CR41 article-title: Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8 T cells in patients with recurrent glioblastoma publication-title: Clin Cancer Res – volume: 851 start-page: 215 year: 1999 end-page: 220 ident: CR57 article-title: Brain endothelial cell production of a neuroprotective cytokine, interleukin-6, in response to noxious stimuli publication-title: Brain Res – volume: 5 start-page: 86 year: 2017 ident: CR24 article-title: Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET Study) [abstract P217] publication-title: J Immunother Cancer – volume: 24 start-page: 731 year: 2018 end-page: 738 ident: CR58 article-title: CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade publication-title: Nat Med – ident: CR78 – volume: 128 start-page: 586 year: 2016 ident: CR81 article-title: Decreased rates of severe CRS seen with early intervention strategies for CD19 CAR-T cell toxicity management publication-title: Blood – volume: 377 start-page: 2545 year: 2017 end-page: 2554 ident: CR11 article-title: Chimeric antigen receptor T cells in refractory B-cell lymphomas publication-title: N Engl J Med – ident: CR64 – volume: 1024 start-page: 138 year: 2004 end-page: 146 ident: CR86 article-title: Glucocorticoids and the Th1/Th2 balance publication-title: Ann N Y Acad Sci – volume: 23 start-page: 430 year: 2017 end-page: 450 ident: CR1 article-title: CARs: synthetic immunoreceptors for cancer therapy and beyond publication-title: Trends Mol Med – volume: 33 start-page: 1688 year: 2015 end-page: 1696 ident: CR34 article-title: Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma publication-title: J Clin Oncol – volume: 130 start-page: 1547 year: 2017 ident: CR45 article-title: Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL) publication-title: Blood – volume: 126 start-page: 3769 year: 2015 ident: CR47 article-title: Efficient trafficking of chimeric antigen receptor (CAR)-modified T cells to CSF and induction of durable CNS remissions in children with CNS/combined relapsed/refractory ALL publication-title: Blood – volume: 136 start-page: 564 year: 2016 end-page: 572 ident: CR63 article-title: Tumour necrosis factor-α-mediated disruption of cerebrovascular endothelial barrier integrity in vitro involves the production of proinflammatory interleukin-6 publication-title: J Neurochem – volume: 378 start-page: 449 year: 2018 end-page: 459 ident: CR2 article-title: Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia publication-title: N Engl J Med – volume: 8 start-page: 958 year: 2018 end-page: 971 ident: CR49 article-title: Clinical and biologic correlates of neurotoxicity associated with CAR T cell therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL) publication-title: Cancer Discov – volume: 6 start-page: 583 year: 2000 end-page: 588 ident: CR69 article-title: Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo publication-title: Nat Med – volume: 21 start-page: 904 year: 2013 end-page: 912 ident: CR37 article-title: Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity publication-title: Mol Ther J Am Soc Gene Ther – volume: 24 start-page: 563 year: 2018 end-page: 571 ident: CR16 article-title: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia publication-title: Nat Med – volume: 35 start-page: 3010 year: 2017 end-page: 3020 ident: CR14 article-title: Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib publication-title: J Clin Oncol – volume: 7 start-page: 1404 year: 2017 end-page: 1419 ident: CR23 article-title: Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells publication-title: Cancer Discov – volume: 37 start-page: 193 year: 2017 end-page: 204 ident: CR32 article-title: Adoptive T-cell therapy for solid tumors publication-title: Am Soc Clin Oncol Educ Book – volume: 16 start-page: 9949 year: 2015 end-page: 9975 ident: CR83 article-title: Pathogenesis of brain edema and investigation into anti-edema drugs publication-title: Int J Mol Sci – volume: 51 start-page: 103 year: 2018 end-page: 110 ident: CR19 article-title: Driving CARs on the uneven road of antigen heterogeneity in solid tumors publication-title: Curr Opin Immunol – volume: 375 start-page: 2561 year: 2016 end-page: 2569 ident: CR42 article-title: Regression of glioblastoma after chimeric antigen receptor T-cell therapy publication-title: N Engl J Med – volume: 126 start-page: 2123 year: 2016 end-page: 2138 ident: CR3 article-title: CD19 CAR-T cells of defined CD4 :CD8 composition in adult B cell ALL patients publication-title: J Clin Investig – volume: 15 start-page: 31 year: 2018 end-page: 46 ident: CR13 article-title: Chimeric antigen receptor T-cell therapies for lymphoma publication-title: Nat Rev Clin Oncol – volume: 23 start-page: 1156 year: 2017 end-page: 1166 ident: CR29 article-title: Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial publication-title: Clin Cancer Res – volume: 118 start-page: 4817 year: 2011 end-page: 4828 ident: CR25 article-title: Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias publication-title: Blood – volume: 11 start-page: 35 issue: 1 year: 2018 ident: CR26 article-title: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel publication-title: J Hematol Oncol – volume: 6 start-page: 224ra25 year: 2014 ident: CR65 article-title: Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia publication-title: Sci Transl Med – volume: 5 start-page: 21 issue: 1 year: 2018 end-page: 42 ident: CR72 article-title: A review of recent advances using tocilizumab in the treatment of rheumatic diseases publication-title: Rheumatol Ther – volume: 8 start-page: 125 year: 2017 end-page: 135 ident: CR89 article-title: Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition publication-title: Adolesc Health Med Ther – volume: 127 start-page: 3462 year: 2017 end-page: 3471 ident: CR27 article-title: Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes publication-title: J Clin Investig – volume: 106 start-page: 1977 year: 2009 end-page: 1982 ident: CR62 article-title: VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown publication-title: Proc Natl Acad Sci USA – volume: 16 start-page: 635 year: 2017 end-page: 661 ident: CR90 article-title: Therapeutic targeting of the angiopoietin-TIE pathway publication-title: Nat Rev Drug Discov – volume: 378 start-page: 439 year: 2018 end-page: 448 ident: CR6 article-title: Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia publication-title: N Engl J Med – volume: 66 start-page: 62 year: 2018 end-page: 64 ident: CR52 article-title: Beginning the CAR T cell therapy revolution in the US and EU publication-title: Curr Res Transl Med – volume: 26 start-page: 1423 year: 2018 end-page: 1434 ident: CR54 article-title: Human CD19-targeted mouse T cells induce B cell aplasia and toxicity in human CD19 transgenic mice publication-title: Mol Ther – volume: 377 start-page: 317 year: 2017 end-page: 328 ident: CR75 article-title: Trial of tocilizumab in giant-cell arteritis publication-title: N Engl J Med – volume: 24 start-page: 739 issue: 6 year: 2018 end-page: 748 ident: CR53 article-title: Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells publication-title: Nat Med – volume: 66 start-page: 1425 year: 2017 end-page: 1436 ident: CR38 article-title: The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity publication-title: Cancer Immunol Immunother – volume: 4 start-page: 507 year: 2013 end-page: 516 ident: CR61 article-title: Biomarkers of endothelial activation/dysfunction in infectious diseases publication-title: Virulence – volume: 29 start-page: 585 year: 2018 end-page: 601 ident: CR18 article-title: Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells publication-title: Hum Gene Ther – volume: 22 start-page: 3322 issue: 129 year: 2017 end-page: 3331 ident: CR4 article-title: Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults publication-title: Blood – volume: 377 start-page: 2531 year: 2017 end-page: 2544 ident: CR12 article-title: Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma publication-title: N Engl J Med – ident: CR44 – volume: 33 start-page: 540 year: 2015 end-page: 549 ident: CR10 article-title: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor publication-title: J Clin Oncol – volume: 55 start-page: 669 year: 2016 end-page: 679 ident: CR74 article-title: Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials publication-title: Rheumatol Oxf Engl – volume: 19 start-page: 3659 year: 2013 end-page: 3670 ident: CR87 article-title: A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease publication-title: Clin Cancer Res – volume: 130 start-page: 2569 year: 2017 end-page: 2572 ident: CR55 article-title: Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights publication-title: Blood – ident: CR17 – volume: 76 start-page: 1257 year: 2016 end-page: 1270 ident: CR36 article-title: Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response publication-title: Prostate – volume: 1 start-page: 432 year: 2009 end-page: 438 ident: CR71 article-title: Tocilizumab publication-title: mAbs – volume: 124 start-page: 188 year: 2014 end-page: 195 ident: CR22 article-title: Current concepts in the diagnosis and management of cytokine release syndrome publication-title: Blood – volume: 127 start-page: 3321 year: 2016 end-page: 3330 ident: CR67 article-title: Toxicities of chimeric antigen receptor T cells: recognition and management publication-title: Blood – volume: 371 start-page: 1507 year: 2014 end-page: 1517 ident: CR7 article-title: Chimeric antigen receptor T cells for sustained remissions in leukemia publication-title: N Engl J Med – volume: 35 start-page: 3019 year: 2017 ident: CR46 article-title: Biomarkers associated with neurotoxicity in adult patients with relapsed or refractory B-ALL (R/R B-ALL) treated with CD19 CAR T cells publication-title: J Clin Oncol – volume: 32 start-page: 87 year: 2015 end-page: 95 ident: CR51 article-title: Consensus statement on continuous EEG in critically ill adults and children. Part I: indications publication-title: J Clin Neurophysiol – volume: 44 start-page: 381 year: 2015 end-page: 388 ident: CR73 article-title: Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources publication-title: Semin Arthritis Rheum – volume: 9 start-page: 207 year: 2014 end-page: 215 ident: CR92 article-title: Management of raised intracranial pressure in children with traumatic brain injury publication-title: J Pediatr Neurosci – volume: 130 start-page: 2295 year: 2017 end-page: 2306 ident: CR20 article-title: Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy publication-title: Blood – volume: 7 start-page: 1404 year: 2017 ident: 582_CR23 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-17-0698 – volume: 6 start-page: 664 year: 2016 ident: 582_CR21 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-16-0040 – volume: 6 start-page: 583 year: 2000 ident: 582_CR69 publication-title: Nat Med doi: 10.1038/75068 – volume: 377 start-page: 2545 year: 2017 ident: 582_CR11 publication-title: N Engl J Med doi: 10.1056/NEJMoa1708566 – volume: 1 start-page: 432 year: 2009 ident: 582_CR71 publication-title: mAbs doi: 10.4161/mabs.1.5.9497 – volume: 15 start-page: 31 year: 2018 ident: 582_CR13 publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2017.128 – volume: 68 start-page: 139 year: 2017 ident: 582_CR33 publication-title: Annu Rev Med doi: 10.1146/annurev-med-062315-120245 – volume: 118 start-page: 4817 year: 2011 ident: 582_CR25 publication-title: Blood doi: 10.1182/blood-2011-04-348540 – volume: 434 start-page: 1 year: 2016 ident: 582_CR79 publication-title: J Immunol Methods doi: 10.1016/j.jim.2016.03.005 – ident: 582_CR44 – volume: 66 start-page: 62 year: 2018 ident: 582_CR52 publication-title: Curr Res Transl Med doi: 10.1016/j.retram.2018.03.004 – volume: 130 start-page: 1547 year: 2017 ident: 582_CR45 publication-title: Blood doi: 10.1182/blood.V130.Suppl_1.1547.1547 – volume: 21 start-page: 2122 year: 2013 ident: 582_CR31 publication-title: Mol Ther J Am Soc Gene Ther doi: 10.1038/mt.2013.154 – volume: 35 start-page: 54 year: 2018 ident: 582_CR91 publication-title: J Neurotrauma doi: 10.1089/neu.2016.4472 – volume: 8 start-page: 355ra116 year: 2016 ident: 582_CR9 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aaf8621 – volume: 15 start-page: 218 year: 2018 ident: 582_CR66 publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2018.19 – volume: 5 start-page: 177ra38 year: 2013 ident: 582_CR15 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3005930 – volume: 127 start-page: 3462 year: 2017 ident: 582_CR27 publication-title: J Clin Investig doi: 10.1172/JCI94306 – volume: 128 start-page: 1688 year: 2016 ident: 582_CR30 publication-title: Blood doi: 10.1182/blood-2016-04-711903 – volume: 6 start-page: 19 year: 1995 ident: 582_CR82 publication-title: Anticancer Drugs doi: 10.1097/00001813-199502000-00002 – volume: 33 start-page: 540 year: 2015 ident: 582_CR10 publication-title: J Clin Oncol doi: 10.1200/JCO.2014.56.2025 – volume: 37 start-page: 193 year: 2017 ident: 582_CR32 publication-title: Am Soc Clin Oncol Educ Book doi: 10.14694/EDBK_180328 – volume: 377 start-page: 317 year: 2017 ident: 582_CR75 publication-title: N Engl J Med doi: 10.1056/NEJMoa1613849 – volume: 35 start-page: 7024 year: 2017 ident: 582_CR60 publication-title: J Clin Oncol doi: 10.1200/JCO.2017.35.15_suppl.7024 – volume: 19 start-page: 944 year: 2013 ident: 582_CR85 publication-title: Contin Minneap Minn – volume: 21 start-page: 904 year: 2013 ident: 582_CR37 publication-title: Mol Ther J Am Soc Gene Ther doi: 10.1038/mt.2013.17 – volume: 15 start-page: 499 year: 2017 ident: 582_CR43 publication-title: Palliat Support Care doi: 10.1017/S147895151600095X – volume: 22 start-page: 799 year: 2016 ident: 582_CR84 publication-title: Contin Minneap Minn – volume: 33 start-page: 1688 year: 2015 ident: 582_CR34 publication-title: J Clin Oncol doi: 10.1200/JCO.2014.58.0225 – volume: 32 start-page: 87 year: 2015 ident: 582_CR51 publication-title: J Clin Neurophysiol doi: 10.1097/WNP.0000000000000166 – volume: 127 start-page: 3321 year: 2016 ident: 582_CR67 publication-title: Blood doi: 10.1182/blood-2016-04-703751 – volume: 9 start-page: 207 year: 2014 ident: 582_CR92 publication-title: J Pediatr Neurosci doi: 10.4103/1817-1745.147572 – volume: 76 start-page: 1257 year: 2016 ident: 582_CR36 publication-title: Prostate doi: 10.1002/pros.23214 – volume: 21 start-page: 4062 year: 2015 ident: 582_CR41 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-0428 – volume: 11 start-page: 35 issue: 1 year: 2018 ident: 582_CR26 publication-title: J Hematol Oncol doi: 10.1186/s13045-018-0571-y – volume: 24 start-page: 731 year: 2018 ident: 582_CR58 publication-title: Nat Med doi: 10.1038/s41591-018-0041-7 – volume: 22 start-page: 3322 issue: 129 year: 2017 ident: 582_CR4 publication-title: Blood doi: 10.1182/blood-2017-02-769208 – volume: 8 start-page: 750 year: 2018 ident: 582_CR48 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-17-1368 – volume: 16 start-page: 635 year: 2017 ident: 582_CR90 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd.2016.278 – volume: 126 start-page: 3769 year: 2015 ident: 582_CR47 publication-title: Blood doi: 10.1182/blood.V126.23.3769.3769 – ident: 582_CR64 – volume: 23 start-page: 943 issue: 8 year: 2018 ident: 582_CR77 publication-title: Oncologist doi: 10.1634/theoncologist.2018-0028 – volume: 1024 start-page: 138 year: 2004 ident: 582_CR86 publication-title: Ann N Y Acad Sci doi: 10.1196/annals.1321.010 – volume: 375 start-page: 2561 year: 2016 ident: 582_CR42 publication-title: N Engl J Med doi: 10.1056/NEJMoa1610497 – volume: 19 start-page: 3659 year: 2013 ident: 582_CR87 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-3349 – volume: 11 start-page: 185 year: 2013 ident: 582_CR59 publication-title: BMC Med doi: 10.1186/1741-7015-11-185 – volume: 59 start-page: 468 year: 2016 ident: 582_CR35 publication-title: Sci China Life Sci doi: 10.1007/s11427-016-5023-8 – volume: 124 start-page: 188 year: 2014 ident: 582_CR22 publication-title: Blood – ident: 582_CR78 – volume: 29 start-page: 585 year: 2018 ident: 582_CR18 publication-title: Hum Gene Ther doi: 10.1089/hum.2018.001 – volume: 126 start-page: 2123 year: 2016 ident: 582_CR3 publication-title: J Clin Investig doi: 10.1172/JCI85309 – volume: 125 start-page: 4017 year: 2015 ident: 582_CR76 publication-title: Blood doi: 10.1182/blood-2014-12-580068 – volume: 385 start-page: 517 year: 2015 ident: 582_CR5 publication-title: Lancet doi: 10.1016/S0140-6736(14)61403-3 – volume: 136 start-page: 564 year: 2016 ident: 582_CR63 publication-title: J Neurochem doi: 10.1111/jnc.13408 – volume: 851 start-page: 215 year: 1999 ident: 582_CR57 publication-title: Brain Res doi: 10.1016/S0006-8993(99)02189-7 – volume: 130 start-page: 2569 year: 2017 ident: 582_CR55 publication-title: Blood doi: 10.1182/blood-2017-08-802413 – volume: 4 start-page: 507 year: 2013 ident: 582_CR61 publication-title: Virulence doi: 10.4161/viru.24530 – volume: 66 start-page: 50 issue: 2 year: 2018 ident: 582_CR68 publication-title: Curr Res Transl Med doi: 10.1016/j.retram.2018.03.003 – volume: 128 start-page: 586 year: 2016 ident: 582_CR81 publication-title: Blood doi: 10.1182/blood.V128.22.586.586 – volume: 371 start-page: 1507 year: 2014 ident: 582_CR7 publication-title: N Engl J Med doi: 10.1056/NEJMoa1407222 – volume: 15 start-page: 47 year: 2018 ident: 582_CR50 publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2017.148 – volume: 5 start-page: 86 year: 2017 ident: 582_CR24 publication-title: J Immunother Cancer doi: 10.1186/s40425-017-0289-3 – volume: 25 start-page: 1248 year: 2017 ident: 582_CR39 publication-title: Mol Ther J Am Soc Gene Ther doi: 10.1016/j.ymthe.2017.03.010 – volume: 6 start-page: 224ra25 year: 2014 ident: 582_CR65 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3008226 – volume: 23 start-page: 430 year: 2017 ident: 582_CR1 publication-title: Trends Mol Med doi: 10.1016/j.molmed.2017.03.002 – volume: 16 start-page: 9949 year: 2015 ident: 582_CR83 publication-title: Int J Mol Sci doi: 10.3390/ijms16059949 – volume: 35 start-page: 3019 year: 2017 ident: 582_CR46 publication-title: J Clin Oncol doi: 10.1200/JCO.2017.35.15_suppl.3019 – volume: 51 start-page: 103 year: 2018 ident: 582_CR19 publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2018.03.002 – volume: 24 start-page: 20 year: 2018 ident: 582_CR28 publication-title: Nat Med doi: 10.1038/nm.4441 – volume: 8 start-page: 958 year: 2018 ident: 582_CR49 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-17-1319 – volume: 112 start-page: 3959 year: 2008 ident: 582_CR80 publication-title: Blood doi: 10.1182/blood-2008-05-155846 – volume: 377 start-page: 2531 year: 2017 ident: 582_CR12 publication-title: N Engl J Med doi: 10.1056/NEJMoa1707447 – volume: 106 start-page: 1977 year: 2009 ident: 582_CR62 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0808698106 – volume: 24 start-page: 739 issue: 6 year: 2018 ident: 582_CR53 publication-title: Nat Med doi: 10.1038/s41591-018-0036-4 – volume: 128 start-page: 2803 year: 2016 ident: 582_CR88 publication-title: Blood doi: 10.1182/blood.V128.22.2803.2803 – volume: 103 start-page: 591 year: 2018 ident: 582_CR8 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.950 – volume: 9 start-page: eaaa0984 issue: 399 year: 2017 ident: 582_CR40 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aaa0984 – volume: 5 start-page: 21 issue: 1 year: 2018 ident: 582_CR72 publication-title: Rheumatol Ther doi: 10.1007/s40744-018-0102-x – volume: 378 start-page: 449 year: 2018 ident: 582_CR2 publication-title: N Engl J Med doi: 10.1056/NEJMoa1709919 – volume: 23 start-page: 1156 year: 2017 ident: 582_CR29 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-1365 – volume: 5 start-page: 683 year: 2005 ident: 582_CR70 publication-title: Expert Opin Biol Ther doi: 10.1517/14712598.5.5.683 – volume: 66 start-page: 1425 year: 2017 ident: 582_CR38 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-017-2034-7 – volume: 142 start-page: 144 year: 1989 ident: 582_CR56 publication-title: J Immunol doi: 10.4049/jimmunol.142.1.144 – volume: 44 start-page: 381 year: 2015 ident: 582_CR73 publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2014.07.006 – ident: 582_CR17 – volume: 55 start-page: 669 year: 2016 ident: 582_CR74 publication-title: Rheumatol Oxf Engl doi: 10.1093/rheumatology/kev382 – volume: 35 start-page: 3010 year: 2017 ident: 582_CR14 publication-title: J Clin Oncol doi: 10.1200/JCO.2017.72.8519 – volume: 8 start-page: 125 year: 2017 ident: 582_CR89 publication-title: Adolesc Health Med Ther doi: 10.2147/AHMT.S109495 – volume: 130 start-page: 2295 year: 2017 ident: 582_CR20 publication-title: Blood doi: 10.1182/blood-2017-06-793141 – volume: 378 start-page: 439 year: 2018 ident: 582_CR6 publication-title: N Engl J Med doi: 10.1056/NEJMoa1709866 – volume: 24 start-page: 563 year: 2018 ident: 582_CR16 publication-title: Nat Med doi: 10.1038/s41591-018-0010-1 – volume: 26 start-page: 1423 year: 2018 ident: 582_CR54 publication-title: Mol Ther doi: 10.1016/j.ymthe.2018.04.006
SSID	ssj0004366
Score	2.6108136
SecondaryResourceType	review_article
Snippet	Neurotoxicity is an important and common complication of chimeric antigen receptor-T cell therapies. Acute neurologic signs and/or symptoms occur in a...
SourceID	pubmedcentral proquest pubmed crossref springer
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	1091
SubjectTerms	Animal models Antigens Antigens, CD19 - metabolism Arthritis Blood-brain barrier Brain cancer CD19 antigen Cell activation Cell therapy Cerebrospinal fluid Chimeric antigen receptors Clinical trials Corticosteroids Cytokines Cytokines - blood Cytokines - cerebrospinal fluid Edema FDA approval Headache Humans Immunologic Factors - therapeutic use Immunotherapy Immunotherapy, Adoptive - methods Interleukin 6 Leading Article Leukemia Lymphocytes Lymphocytes B Lymphocytes T Lymphoma Medicine Medicine & Public Health Multiple myeloma Neurology Neurosciences Neurotoxicity Neurotoxicity Syndromes - epidemiology Neurotoxicity Syndromes - immunology Neurotoxicity Syndromes - metabolism Neurotoxicity Syndromes - therapy Pediatrics Pharmacotherapy Psychiatry Psychopharmacology Receptors, Antigen, T-Cell - metabolism Seizures Traumatic brain injury Young adults
SummonAdditionalLinks	– databaseName: Health & Medical Collection dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB5R6KGXlkcfaQG5EuLQYjWxnTo5FbSAOFRohbbV3qLED3WlVZayS1X-fWe8eWhBcOklh3jysGbGnvHMfANwgEKgpDGSV1Z7riqveOZQr0IRJK4N2of2bT-_68vLbDzOh82B27xJq2zXxLBQ25mhM_IvqFmSrF-RfLv-zalrFEVXmxYaz2CD2maTnOux7usiZYhVJrhJcx0r3UY1qXQO_SaKYCYZj1M0MvPVfemBsfkwZ_Je4DTsR-ev_ncmm_CysUTZyVJ0tmDN1dtwOFxCWd8dsVFfmTU_Yods2INc3-3AcUD1WMz-Tgza8azlsrOMTnbZ4DTJ-ShkmeOtwckVH7GBm06bt6J7_hp-nJ-NBhe86cbAjdLxgqMbXVr0zqpMGeGNV05VOrV5QgA2aZmKrBQmL9HCMVIJ7YRD97cqlZUxXisv38B6PavdO2DIC-9EbtH08yr16PXZMqYmRlXpna1MBHHLi8I0UOXUMWNadCDLgX0Fsq8g9hV5BJ-6R66XOB1PEe-2nCkalZ0XPVsi-NgNo7JRBKWs3eyWaASl48qvSPN2KQ_d1yQlAsRaR6BXJKUjICDv1ZF68isAeqODg3ZvGsHnVqb633p0Eu-fnsQHeCFIukPmzS6sL25u3R48N38Wk_nNftCTf6n_GBM priority: 102 providerName: ProQuest
Title	Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
URI	https://link.springer.com/article/10.1007/s40263-018-0582-9 https://www.ncbi.nlm.nih.gov/pubmed/30387077 https://www.proquest.com/docview/2193559721 https://www.proquest.com/docview/2129533361 https://pubmed.ncbi.nlm.nih.gov/PMC7295115
Volume	32
WOSCitedRecordID	wos000452919800002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1179-1934 dateEnd: 20241212 omitProxy: false ssIdentifier: ssj0004366 issn: 1172-7047 databaseCode: 7X7 dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1179-1934 dateEnd: 20241212 omitProxy: false ssIdentifier: ssj0004366 issn: 1172-7047 databaseCode: BENPR dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1179-1934 dateEnd: 20241212 omitProxy: false ssIdentifier: ssj0004366 issn: 1172-7047 databaseCode: M2M dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Nature - Connect here FIRST to enable access customDbUrl: eissn: 1179-1934 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004366 issn: 1172-7047 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swED-NDyFe2MbHCGOVJyEeAEuJ7eDkDdaBeKBVVQrqW5Q4toZUpYgGRP97zm6SqmNM2l4iJT47jn2273J3vwM4QCYQXClOs1waKjIjaKRxXbkgSNwbpHHp2-6uZbcbDYdxr4rjntTe7rVJ0u3UTbAbajrW5hhE1A9RLIyXYAVPu8jma-jf3M2DIbkzUAZ4MlPpC1mbMv_UxOJh9EbCfOso-Zu11B1Clx__q_ufYKOSOcn5jEk-wwddbMJap7Kqb8Jhb4ZfPT0hg3k41uSEHJLeHNl6ugVnDsqjHL9gxXJK6qnVObG_c0n7ZxDTgXMtx0ft8z4dkLYejapWUSffhtvLi0H7ilYpGKgS0i8p6s5pjipZFgnFjDJCi0yGeRxY1JowDVmUMhWnKNYoLpjUTKPOm6Ui5z5eM8N3YLkYF3oXCM6F0SzOUd4zIjSo6uWpbzMXZanReaY88Ou5SFSFT27TZIySBlnZDWGCQ5jYIUxiD46aKg8zcI6_Ee_XE5xU63SS4H7NrU7FAg--N8W4wqzZJC30-MnSMOuDy0-R5suMH5q3cWv996X0QC5wSkNg0bsXS4r7Xw7FG7UaFHZDD45rfpl3692P2Psn6q-wzizDOe-bfVguH5_0N1hVz-X95LEFS3Io3TVqwcqPi26vj3cd1mm5BfUKEmAVIw
linkProvider	Springer Nature
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VggQX3g9DgUWCHqAr7PWatQ8IqpSqVUMUoYByM_Z6V0SKnFKnQP4Uv5GZ9UuhorceuOQQbxyv95vZmZ2ZbwCeIwhkqHXI80JZLnMreWxQrlwRJOoGZV37ti9DNRrF02ky3oDfbS0MpVW2OtEp6mKh6Yz8NUpWSNavCN4df-fUNYqiq20LjRoWR2b1E1226u3hHq7vCyH2P0wGB7zpKsC1VP6SozuYFehl5LHUwmorjcxVVCQBEbFEWSTiTOgkw51ah1IoIwy6cXkmi9DHz9yGeN9LcBn1uCJnT01VX4cZuthogEYBV75UbRSVSvXQT6OIaRBzP0KjNlnfB88Yt2dzNP8K1Lr9b__G__bmbsL1xtJmu7Vo3IINU96G7XFN1b3aYZO-8qzaYdts3JN4r-7Ae8daslz8mmn0U1iLYlMwOrlmg70g4ROXRY9fDXY_8QkbmPm8uevMVHfh84XM7h5slovSPACGa2-NSAo0ba2MLHq1ReZTk6Y8s6bItQd-u_apbqjYqSPIPO1IpB1cUoRLSnBJEw9edj85rnlIzhu81SIhbVRSlfYw8OBZdxmVCUWIstIsTmmMoHTj8A2OuV_jr_u3kBIdfKU8UGvI7AYQUfn6lXL2zRGWowOHdn3kwasWw_1j_XMSD8-fxFO4ejD5OEyHh6OjR3BNkGS5LKMt2FyenJrHcEX_WM6qkydORhl8vWho_wEjs3Sv
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VghAX3o9AASNBD1CriePg5ICg2mVF1bJaoQX1FhLHFiutsqXZAvvX-HXMOC8tFb31wCWHxHk4-WY8k5n5BuA5gkCGWoc8L5TlMreSxwblyhVBom5Q1rVv-3KoxuP46CiZbMDvthaG0ipbnegUdbHQ9I98FyUrJOtXBLu2SYuYDEdvj79z6iBFkda2nUYNkQOz-onuW_Vmf4jf-oUQo_fTwQfedBjgWip_ydE1zAr0OPJYamG1lUbmKiqSgEhZoiwScSZ0kuGqrUMplBEGXbo8k0Xo4za3IV73ElxWEu0OShsUH_uazNDFSQM0ELjypWojqlS2hz4bRU-DmPsRGrjJ-pp4xtA9m6_5V9DWrYWjG__zW7wJ1xsLnO3VInMLNkx5G7YnNYX3aodN-4q0aodts0lP7r26A-8cm8ly8Wum0X9hLbpNweiPNhsMg4RPXXY97hrsfeJTNjDzeXPVmanuwucLmd092CwXpXkADHFgjUgKNHmtjCx6u0XmU_OmPLOmyLUHfouDVDcU7dQpZJ525NIOOilCJyXopIkHL7tTjmt-kvMGb7WoSBtVVaU9JDx41h1GJUORo6w0i1MaIygNOXyNY-7XWOzuFlIChK-UB2oNpd0AIjBfP1LOvjkic3Ts0N6PPHjV4rl_rH9O4uH5k3gKVxHR6eH--OARXBMkZC75aAs2lyen5jFc0T-Ws-rkiRNXBl8vGtl_AOf3fXI
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neurotoxicity+Associated+with+CD19-Targeted+CAR-T+Cell+Therapies&rft.jtitle=CNS+drugs&rft.au=Gust%2C+Juliane&rft.au=Taraseviciute%2C+Agne&rft.au=Turtle%2C+Cameron+J&rft.date=2018-12-01&rft.issn=1179-1934&rft.eissn=1179-1934&rft.volume=32&rft.issue=12&rft.spage=1091&rft_id=info:doi/10.1007%2Fs40263-018-0582-9&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1172-7047&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1172-7047&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1172-7047&client=summon